Depicting median MC percentage and tryptase levels in study groups
Parameter
Group
Number
Median [in % (IQR)]
p-value
Mast cell(in %)
Patient
30
0.04 (0.015–0.074)
0.00001
Control
20
0.002 (0.001–0.006)
Tryptase(in ng/mL)
Patient
30
10.1 (6.4–16.9)
0.011
Control
20
7.0 (3.7–8.1)
Group
Number
Positive
Negative
p-value
Patient
30
15
15
0.003
Control
20
2
18
Declarations
Author contributions
RY: Writing—original draft, Writing—review & editing. RT: Investigation, Data curation, Formal analysis, Writing—original draft. RWM: Writing—review & editing, Supervision. PM: Data curation. YK: Conceptualization, Data curation, Formal analysis, Writing—review & editing. All authors have read and approved the manuscript.
Conflicts of interest
None of the authors has any conflict of interest to disclose.
Ethical approval
The study was approved by the Institute Ethics Committee (IEC), PGIMER, Chandigarh, 160012, India (No: INT/IEC/2019/000143).
Consent to participate
Informed consent to participate in the study was obtained from all participants.
Consent to publication
Not applicable.
Availability of data and materials
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.
Funding
The work has been supported by the Post Graduate Institute of Medical Education & Research, Chandigarh, India, Grant No. [71/8-Edu-15/1734]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
McKenna AW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein DH, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2017. pp. 239–58.
Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. William’s hematology, 9th edition. New York: McGraw-Hill; 2015. pp. 1707–803.
Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, et al. The significant role of mast cells in cancer.Cancer Metastasis Rev. 2011;30:45–60. [DOI] [PubMed]
He L, Zhu Z, Chen S, Wang Y, Gu H. Mammary tumor growth and metastasis are reduced in c-Kit mutant Sash mice.Cancer Med. 2016;5:1292–7. [DOI] [PubMed] [PMC]
Cinel L, Aban M, Basturk M, Ertunc D, Arpaci R, Dilek S, et al. The association of mast cell density with myometrial invasion in endometrial carcinoma: a preliminary report.Pathol Res Pract. 2009;205:255–8. [DOI]
Roy A, Attarha S, Weishaupt H, Edqvist P, Swartling FJ, Bergqvist M, et al. Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression.Oncotarget. 2017;8:24815–27. [DOI] [PubMed] [PMC]
Fukushima N, Satoh T, Sano M, Tokunaga O. Angiogenesis and mast cells in non-Hodgkin’s lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma.Leuk Lymphoma. 2001;42:709–20. [DOI] [PubMed]
Stoyanov E, Uddin M, Mankuta D, Dubinett SM, Levi-Schaffer F. Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells.Lung Cancer. 2012;75:38–44. [DOI] [PubMed]
Maciel TT, Moura IC, Hermine O. The role of mast cells in cancers.F1000Prime Rep. 2015;7:09. [DOI] [PubMed] [PMC]
Devetzoglou M, Vyzoukaki R, Kokonozaki M, Xekalou A, Pappa CA, Papadopoulou A, et al. High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.Tumour Biol. 2015;36:8491–7. [DOI] [PubMed]
Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth.Biochim Biophys Acta. 2012;1822:2–8. [DOI] [PubMed]
Escribano L, Garcia Montero AC, Núñez R, Orfao A; Red Española de Mastocitosis. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease.Immunol Allergy Clin North Am. 2006;26:535–47. [DOI] [PubMed]
Gudiseva S, Santosh ABR, Chitturi R, Anumula V, Poosarla C, Baddam VRR. The role of mast cells in oral squamous cell carcinoma.Contemp Oncol (Pozn). 2017;21:21–9. [DOI] [PubMed] [PMC]
Ghanem S, Garcia G, Ying L, Hurford M, Odaimi M. Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case.Case Rep Oncol Med. 2016;2016:3161768. [DOI] [PubMed] [PMC]
Zanelli M, Ricci S, Zizzo M, Sanguedolce F, De Giorgi F, Palicelli A, et al. Systemic Mastocytosis Associated with “Smoldering” Multiple Myeloma.Diagnostics (Basel). 2021;11:88. [DOI] [PubMed] [PMC]
Nico B, Mangieri D, Crivellato E, Vacca A, Ribatti D. Mast cells contribute to vasculogenic mimicry in multiple myeloma.Stem Cells Dev. 2008;17:19–22. [DOI] [PubMed]
Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors.J Clin Invest. 2004;114:1317–25. [DOI] [PubMed] [PMC]
Pappa CA, Tsirakis G, Devetzoglou M, Zafeiri M, Vyzoukaki R, Androvitsanea A, et al. Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.Tumour Biol. 2014;35:5647–51.
Vyzoukaki R, Tsirakis G, Pappa CA, Devetzoglou M, Tzardi M, Alexandrakis MG. The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients.Int Arch Allergy Immunol. 2015;168:263–8. [DOI] [PubMed]
Pappa CA, Tsirakis G, Stavroulaki E, Kokonozaki M, Xekalou A, Konsolas I, et al. Mast cells influence the proliferation rate of myeloma plasma cells.Cancer Invest. 2015;33:137–41. [DOI] [PubMed]
Vyzoukaki R, Tsirakis G, Pappa CA, Androulakis N, Kokonozaki M, Tzardi M, et al. Correlation of Mast Cell Density With Angiogenic Cytokines in Patients With Active Multiple Myeloma.Clin Ther. 2016;38:297–301. [DOI] [PubMed]
Ribatti D, Tamma R, Vacca A. Mast Cells and Angiogenesis in Human Plasma Cell Malignancies.Int J Mol Sci. 2019;20:481. [DOI] [PubMed] [PMC]
Paolino G, Moliterni E, Didona D, Cardone M, Lopez T, Garelli V, et al. Serum tryptase levels in melanoma patients: case-control study and review of the literature.G Ital Dermatol Venereol. 2019;154:18–25. [DOI] [PubMed]
Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma.Oncogene. 2006;25:4257–66. [DOI] [PubMed]
Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma.Leukemia. 2006;20:193–9. [DOI] [PubMed]
Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B.Nat Immunol. 2007;8:1095–104. [DOI] [PubMed]
Atiakshin D, Kulchenko N, Kostin A, Ignatyuk M, Protasov A, Klabukov I, et al. Cyto- and Histopographic Assessment of CPA3-Positive Testicular Mast Cells in Obstructive and Non-Obstructive Azoospermia.Cells. 2024;13:833. [DOI] [PubMed] [PMC]
Óskarsson JÞ, Rögnvaldsson S, Thorsteinsdottir S, Aspelund T, Gunnarsson SB, Hákonardóttir GK, et al. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index.Blood Cancer J. 2023;13:177. [DOI] [PubMed] [PMC]
Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, et al. Pharmacological treatment options for mast cell activation disease.Naunyn Schmiedebergs Arch Pharmacol. 2016;389:671–94. [DOI] [PubMed] [PMC]
